Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 10:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 290 matching trials from the live ClinicalTrials.gov search.
Conditions
Lymphoma
Interventions
rituximab, CHOP regimen, cyclophosphamide, doxorubicin hydrochloride, prednisone, vincristine sulfate
Biological · Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
60 Years and older
Enrollment
630 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2006
U.S. locations
91
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 60 more
Conditions
Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Minimal Residual Disease
Interventions
Dasatinib, Imatinib Mesylate, Laboratory Biomarker Analysis, Nilotinib, Pembrolizumab
Drug · Other · Biological
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2031
U.S. locations
291
States / cities
Fairbanks, Alaska • Goodyear, Arizona • Phoenix, Arizona + 209 more
Conditions
Anemia, Fatigue, Prostate Cancer
Interventions
epoetin alfa, dexamethasone
Biological · Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 120 Years · Male only
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
140
States / cities
Modesto, California • Aurora, Colorado • Boulder, Colorado + 92 more
Conditions
Human Papilloma Virus Infection, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage IVA Squamous Cell Carcinoma of the Oropharynx, Stage IVB Squamous Cell Carcinoma of the Oropharynx
Interventions
Transoral surgery, intensity-modulated radiation therapy, cisplatin, carboplatin
Procedure · Radiation · Drug
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
519 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
58
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 44 more
Conditions
Cervical Cancer
Interventions
recombinant interleukin-12
Biological
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2005
U.S. locations
9
States / cities
Boston, Massachusetts • Flemington, New Jersey • Hackensack, New Jersey + 6 more
Conditions
Leukemia
Interventions
filgrastim, recombinant interferon alfa, busulfan, cytarabine, etoposide, hydroxyurea, idarubicin, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
15 Years to 65 Years
Enrollment
744 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
2
States / cities
Hackensack, New Jersey • Red Bank, New Jersey
Conditions
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
Interventions
piritrexim
Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 120 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2004
U.S. locations
28
States / cities
Atlanta, Georgia • Decatur, Georgia • Chicago, Illinois + 19 more
Conditions
Clinical Stage IV Esophageal Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8, Clinical Stage IVA Gastric Cancer AJCC v8, Clinical Stage IVB Esophageal Adenocarcinoma AJCC v8, Clinical Stage IVB Gastric Cancer AJCC v8, Metastatic Esophageal Adenocarcinoma, Metastatic Gastric Adenocarcinoma, Oligometastatic Esophageal Adenocarcinoma, Oligometastatic Gastric Adenocarcinoma, Pathologic Stage IV Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IV Gastric Cancer AJCC v8, Pathologic Stage IVA Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IVB Esophageal Adenocarcinoma AJCC v8
Interventions
Capecitabine, Fluorouracil, Leucovorin, Leucovorin Calcium, Oxaliplatin, Radiation Therapy
Drug · Radiation
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
453
States / cities
Anchorage, Alaska • Kingman, Arizona • Phoenix, Arizona + 276 more
Conditions
Breast Cancer, Cognitive/Functional Effects, Colorectal Cancer, Lung Cancer, Pain, Prostate Cancer, Psychosocial Effects of Cancer and Its Treatment
Interventions
assessment of therapy complications, cognitive assessment, psychosocial assessment and care
Procedure
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 120 Years
Enrollment
2,310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
32
States / cities
Chicago, Illinois • Evanston, Illinois • Elkhart, Indiana + 19 more
Conditions
Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer, Signet Ring Adenocarcinoma of the Colon, Signet Ring Adenocarcinoma of the Rectum, Stage IIIA Colon Cancer, Stage IIIA Rectal Cancer, Stage IIIB Colon Cancer, Stage IIIB Rectal Cancer, Stage IIIC Colon Cancer, Stage IIIC Rectal Cancer, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Rectal Cancer
Interventions
irinotecan hydrochloride, oxaliplatin, leucovorin calcium, fluorouracil, quality-of-life assessment
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
560 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Interventions
Quality-of-Life Assessment, Questionnaire Administration
Other
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years to 39 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
347
States / cities
Fairbanks, Alaska • Kingman, Arizona • Phoenix, Arizona + 215 more
Conditions
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Peritoneal Carcinomatosis
Interventions
Standard of Care Chemotherapy, Biospecimen Collection, Computed Tomography, Diagnostic Laparoscopy, Intraperitoneal Port Placement, Magnetic Resonance Imaging, Intraperitoneal Paclitaxel
Drug · Procedure
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
78
States / cities
Irvine, California • Los Angeles, California • Orange, California + 64 more
Conditions
Gastrointestinal Stromal Tumor
Interventions
Conventional Surgery, Imatinib Mesylate
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Lung Cancer
Interventions
carboplatin, paclitaxel, conventional surgery
Drug · Procedure
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
354 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2012
U.S. locations
267
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 197 more
Conditions
Lung Cancer
Interventions
cisplatin, etoposide, conventional surgery, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
429 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2013
U.S. locations
15
States / cities
Urbana, Illinois • Indianapolis, Indiana • Cedar Rapids, Iowa + 10 more
Conditions
Anal Basaloid Carcinoma, Anal Canal Cloacogenic Carcinoma, Anal Squamous Cell Carcinoma, Metastatic Anal Canal Carcinoma, Recurrent Anal Canal Carcinoma, Stage IIIB Anal Canal Cancer, Stage IV Anal Canal Cancer
Interventions
Capecitabine, Carboplatin, Cisplatin, Fluorouracil, Laboratory Biomarker Analysis, Paclitaxel, Quality-of-Life Assessment
Drug · Other
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Lymphoma
Interventions
rituximab, cyclophosphamide, doxorubicin, prednisone, vincristine, tositumomab
Biological · Drug · Radiation
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
571 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2025
U.S. locations
259
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Fort Smith, Arkansas + 167 more
Conditions
Lung Cancer
Interventions
cisplatin, docetaxel, etoposide, conventional surgery, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
Not listed
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
154
States / cities
Mobile, Alabama • Fort Collins, Colorado • Jacksonville, Florida + 97 more
Conditions
Gastric Cancer
Interventions
cisplatin, fluorouracil, leucovorin calcium, paclitaxel, surgery, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2011
U.S. locations
30
States / cities
Denver, Colorado • Atlanta, Georgia • Chicago, Illinois + 23 more
Conditions
Gastrointestinal Stromal Tumor
Interventions
Imatinib Mesylate
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
15 Years and older
Enrollment
748 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2014
U.S. locations
132
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 99 more
Conditions
Lymphoma
Interventions
rituximab, CHOP regimen, carmustine, cyclophosphamide, doxorubicin hydrochloride, etoposide, prednisone, vincristine sulfate, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
15 Years to 65 Years
Enrollment
397 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2013
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Plasma Cell Myeloma, RISS Stage I Plasma Cell Myeloma, RISS Stage II Plasma Cell Myeloma
Interventions
Bortezomib, Daratumumab and Hyaluronidase-fihj, Dexamethasone, Lenalidomide, Quality-of-Life Assessment
Drug · Biological · Other
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
1,450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
640
States / cities
Anchorage, Alaska • Phoenix, Arizona • Tucson, Arizona + 456 more
Conditions
Gastrinoma, Glucagonoma, Insulinoma, Islet Cell Carcinoma, Pancreatic Polypeptide Tumor, Recurrent Islet Cell Carcinoma, Somatostatinoma
Interventions
temozolomide, capecitabine
Drug
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
323
States / cities
Anaheim, California • Antioch, California • Baldwin Park, California + 221 more
Conditions
Anaplastic Large Cell Lymphoma, ALK-Negative, Follicular Helper T-Cell Lymphoma, Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type, Peripheral T-Cell Lymphoma, Not Otherwise Specified
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Best Practice, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, High Dose Chemotherapy, Leukapheresis, Positron Emission Tomography, Stem Cell Mobilization Therapy
Procedure · Other · Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 75 Years
Enrollment
294 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2075
U.S. locations
164
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 123 more